Comparative Effectiveness and Coordinated Care in Migraines: What Does Managed Care Need to Know about Anti-CGRP Therapies?

A continuing medical education activity sponsored by NAMCP and AAMCN.

The Promise of CGRP Targeted Therapies in the Treatment and Prevention of Migraines: What Managed Care Needs to Know in the Evolving Treatment Paradigm is a 3-part webcast series that will provide attendees with the latest information in the management of migraines.

This is Part 3 of the series focusing on what managed care needs to know about anti-CGRP therapies

This activity is an archive from the webinar held June 27, 2019

This activity is valid from July 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
Teva Pharmaceuticals

Description:
Migraine is a major neurological disease that affects more than 36 million men, women and children in the US. Migraine headache is the most common type of headache presented by patients that seek medical treatment, and the WHO has ranked migraine in the top fifteen most disabling medical conditions. Although approximately 38% of migraineurs need preventive therapy, only 3% to 13% currently use it. Fortunately for patients who suffer from migraine headaches, a new class of therapy is emerging that has shown to offer vastly improved efficacy and safety over traditional treatment regimens. Three calcitonin gene-related peptide (CGRP) monoclonal antibodies have recently been approved that offer healthcare professionals a new and improved armamentarium in the treatment and prevention of migraines.

Upon completion of this activity, participants will be able to:

  • Examine the impact migraine has on pharmacoeconomics and total cost of patient care

  • Assess the managed care considerations of anti-CGRP therapies by exploring where the implementation of these agents into the evolving migraine treatment paradigm

  • Discuss methods to enable optimal cost management of anti-CGRP therapies to be realized by multiple migraine stakeholders including managed care organizations

  • Explore interventions to coordinate health plan and affiliated provider's efforts that will lead to better outcomes for patients with migraines
     

Faculty: Gary Owens, MD
President
Gary Owens Associates

Disclosure:

Dr. Owens serves on an advisory board for Allergan and Amgen.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
Teva Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue